AVALO THERAPEUTICS INC (AVTX) Stock News
NASDAQ:AVTX - Nasdaq - US05338F3064 - Common Stock - Currency: USD
AVTX Latest News, Press Relases and Analysis
Avalo Adds Dr. Rita Jain to Board as LOTUS Trial Advances
Avalo Therapeutics, Inc. (NASDAQ:AVTX) is among the best growth stocks to invest in for the next 5 years. On Monday, the management of Avalo Therapeutics, Inc. (NASDAQ:AVTX) revealed its participation in the HCW Annual Inflammation & Immunology Virtual Conference, scheduled for June 30, 2025, and BTIG Virtual Biotechnology Conference 2025, planned for July 29–30, 2025. […]
Avalo Therapeutics to Participate in Upcoming Investor Conferences
WAYNE, Pa., June 23, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company focused on the treatment of...
Avalo Therapeutics to Participate in Upcoming Investor Conferences
Avalo Therapeutics Announces Appointment of Rita Jain, M.D. to Board of Directors
WAYNE, Pa., June 18, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company focused on the treatment of...
AVTX Stock Earnings: Avalo Therapeutics Misses EPS for Q2 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Avalo Therapeutics (NASDAQ:AVTX) just reported results for the second quarter o...
AVTX Stock Earnings: Avalo Therapeutics Misses EPS for Q2 2024
AVTX stock results show that Avalo Therapeutics missed analyst estimates for earnings per share the second quarter of 2024.
Avalo Therapeutics Announces Appointment of Rita Jain, M.D. to Board of Directors
Avalo Therapeutics to Participate in Upcoming Investor Conferences
Avalo Therapeutics to Participate in Upcoming Investor Conferences
WAYNE, Pa. and ROCKVILLE, Md., May 27, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company focused...
Avalo Reports First Quarter 2025 Financial Results and Recent Business Updates
Mike Heffernan appointed as Chairman of the Board Topline data from Phase 2 LOTUS trial of AVTX-009 for the treatment of hidradenitis suppurativa expected...
Avalo Reports First Quarter 2025 Financial Results and Recent Business Updates
Avalo Therapeutics to Participate in The Citizens Life Sciences Conference
WAYNE, Pa. and ROCKVILLE, Md., April 30, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company focused...
Avalo Therapeutics to Participate in The Citizens Life Sciences Conference
Avalo Therapeutics Appoints Michael Heffernan as Chairman of the Board
WAYNE, Pa. and ROCKVILLE, Md., March 26, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical-stage biotechnology company...
Avalo Therapeutics Appoints Michael Heffernan as Chairman of the Board
Avalo Reports 2024 Financial Results and Recent Business Updates
Topline data from Phase 2 LOTUS Trial of AVTX-009 for the treatment of hidradenitis suppurativa expected in 2026 Appointed Jennifer Riley as Chief Strategy...
Avalo Reports 2024 Financial Results and Recent Business Updates
Avalo Therapeutics to Participate in Upcoming Investor Conferences
Avalo Therapeutics to Present at Oppenheimer’s 35th Annual Healthcare Life Sciences Conference
WAYNE, Pa. and ROCKVILLE, Md. , Feb. 04, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company focused...
Avalo Therapeutics to Present at Oppenheimer’s 35th Annual Healthcare Life Sciences Conference
Avalo Therapeutics Appoints Jennifer Riley as Chief Strategy Officer
WAYNE, Pa. and ROCKVILLE, Md., Jan. 02, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company focused...
Avalo Therapeutics Appoints Jennifer Riley as Chief Strategy Officer
Avalo Therapeutics Receives $69.4 Million in Proceeds from the Full Exercise of Private Placement Warrants
Proceeds from the full exercise of warrants issued in the first quarter of 2024 private placement bring the total gross proceeds from the transaction to...
Avalo Therapeutics Receives $69.4 Million in Proceeds from the Full Exercise of Private Placement Warrants
Avalo Therapeutics to Present at Upcoming Investor Conferences
WAYNE, Pa. and ROCKVILLE, Md., Nov. 11, 2024 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company focused...
Avalo Therapeutics to Present at Upcoming Investor Conferences
Avalo Reports Third Quarter 2024 Financial Results and Recent Business Updates
Dosed first patient in Phase 2 LOTUS Trial of AVTX-009 for the treatment of hidradenitis suppurativa (HS), with topline data expected in 2026Cash position...
Avalo Reports Third Quarter 2024 Financial Results and Recent Business Updates
Avalo Announces First Patient Dosed in Phase 2 LOTUS Trial of AVTX-009 for the Treatment of Hidradenitis Suppurativa
Global study in approximately 180 adults with hidradenitis suppurativa to assess the efficacy and safety of two dose regimens of AVTX-009 compared to...
Avalo Announces First Patient Dosed in Phase 2 LOTUS Trial of AVTX-009 for the Treatment of Hidradenitis Suppurativa
Avalo Announces Participation in September Investor Conferences
Avalo Reports Second Quarter 2024 Financial Results and Provides Business Updates
Expects to enroll first patient in Phase 2 LOTUS Trial of AVTX-009 in hidradenitis suppurativa in the second half of 2024Appointed Dr. Mittie Doyle as...